BioChem Pharma Says Emory Patent Claims Invalid.LAVAL, QUEBEC--(BUSINESS WIRE)--Oct. 15, 1996--BIOCHEM PHARMA INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (ME;TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). ;NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on BCH BCH Beach BCH Banco Central de Honduras BCH Boot Console Handler BCH Boulder Community Hospital (Boulder, CO, USA) BCH Broadcast Channel BCH Belfast City Hospital BCH Banco Central-Hispano ;BCHXF) BioChem Pharma filed a response today to a patent infringement suit brought by Emory University. BioChem Pharma is the Canadian-based biopharmaceutical company that discovered EpivirO/3TCr (lamivudine), the most widely prescribed drug for the treatment of HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome . BioChem Pharma and its co-founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dr. Francesco Bellini, welcome the opportunity to have the patent issue settled through the U.S. legal system. "The federal courts provide us with the appropriate forum to finally put to rest Emory University's baseless claims to 3TCr. Their action does a grave disservice to the late Dr. Belleau and all of the brilliant and dedicated scientists, who pioneered this discovery, which is currently providing a treatment that makes a difference to so many people suffering from HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. infection." BioChem Pharma responded in court papers filed today to Emory's allegations. Emory has based its claims on its July 1996 U.S. patent. However, BioChem Pharma has had the pioneering patent covering 3TCr since 1991 and its licensee, Glaxo Wellcome plc, has manufactured and sold 3TCr (EpivirO) since 1995. The Emory patent is invalid as it fails to comply with the most fundamental requirements of U.S. patent law. Emory improperly incorporated 3TCr into their patent application long after it had been invented and made public by BioChem Pharma and Glaxo Wellcome. Under its licensing agreement with Glaxo Wellcome, BioChem Pharma receives royalties based on sales of 3TCr (EpivirO) and it is a portion of those royalties that Emory wishes to unjustly appropriate. BioChem Pharma, soon to mark its tenth anniversary, is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention, detection, and treatment of human diseases. The company shares are traded on the Montreal and Toronto Stock exchanges (BCH) and on the NASDAQ (BCHXF). CONTACT: BioChem Pharma Inc. Christine Lennon, 514/978-7938 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion